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neutropenia or neutropenia from other causes among patients
taking clopidogrel in CAPRIE from the neutropenia seen in .1%
of patients treated with ticlopidine for greater than 1 month in
whom profound life-threatening neutropenia develops requiring
cessation of the drug and often requiring therapeutic interventions.
This sort of severe neutropenia did not occur in any of the more
than 9,000 patients in CAPRIE treated with clopidogrel and has
been reported very rarely in the greater than 4 million people
treated with clopidogrel since the drug was approved for use in the
United States based on post-market surveillance (Dr. Melvin
Blumenthal, MD, Bristol-Myers Squibb, personal communication).
In conclusion, the frequency of neutropenia among patients
taking clopidogrel appears to be similar to the background occur-
rence of neutropenia in patients taking aspirin, and the evidence
from CAPRIE and all other randomized trials suggests clopidogrel
does not cause neutropenia, as we stated in the article.
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Improvement of Myocardial
Blood Flow to Ischemic Regions by
Angiotensin-Converting Enzyme Inhibition
Schneider et al. (1) analyzed the effects of acute angiotensin-
converting enzyme (ACE) inhibition on myocardial blood flow
(MBF) in ischemic and nonischemic regions of 10 symptomatic
patients with coronary artery disease (CAD). They used [15O] water
positron emission tomography at rest and during maximal dobut-
amine stress before and after angiotensin converting enzyme (ACE)
inhibition and demonstrated that quinaprilat 10 mg intravenous was
able to improve MBF to ischemic regions in patients with CAD.
There is some experimental and clinical evidence that ACE
inhibitors can increase regional oxygen supply to ischemic areas of
myocardium through a redistribution of regional blood flow in
humans and animals (2–7). However, there is not evidence that
ACE-inhibitors are able to improve the main clinical outcomes in
evaluation of anti-ischemic efficacy of cardiovascular drugs as
angina, ST segment depression and echocardiographic wall motion
abnormalities during exercise or pharmacological stress test. In this
regard we demonstrated, using exercise and dipyridamole echocar-
diographic stress tests, that neither captopril nor enalapril (sulfhy-
dryl and not sulfhydryl ACE-inhibitors, respectively) had a signif-
icant antiischemic effect in patients with stable angina pectoris (8).
In our point of view, the main questions are: Has the improve-
ment of MBF induced by acute administration of quinaprilat a
clinical significance? Is it useful to evaluate the effects of a
cardiovascular drug by an advanced technique as [15O] water
positron emission tomography without the evidence of clinical,
mechanical or electrocardiographic markers of myocardial ischemia
in all patients during stress test?
Analyzing the methods used by authors (1), we found that most
patients did not have clinical, electrocardiographic or mechanical
criteria of ischemia during dobutamine stress test. Therefore, there
is not evidence in the results section that the quinaprilat is able to
reduce myocardial ischemia. This restricts the relevance of the
conclusions for the average clinical reader. We think that the
quinaprilat-induced changes in MBF are not enough to establish
whether ACE-inhibitors are the anti-ischemic drugs or not.
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REPLY
We appreciate the interest of Dr. Langobardi and his colleagues
concerning our analysis of the antiischemic effect of 10 mg
quinapril (intravenous) assessed by 15O water positron emission
tomography (PET) (1) and questioning the clinical value of our
observation. The clear advantage of the PET technique we have
used is the noninvasive, quantitative analysis of changes in regional
myocardial blood flow, which is currently only possible with
positron tracers. Using this technique a significant improvement in
myocardial blood flow after quinaprilat intravenous could be
demonstrated. We agree with Dr. Langobardi that the incidence of
clinical signs of ischemia was low in our patient population as it was
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observed by others in patients with coronary artery disease under-
going dobutamine-stress (2). However, the PET technique en-
abled us to detect very early changes in myocardial blood flow
before these clinical signs of ischemia eventually developed. Since
we know that the presence of clinical signs of ischemia are
inconsistent, subjective and variable in the same patient, we
decided to focus on quantifiable, regional measures of myocardial
blood flow.
In contrast to Dr. Langobardi’s statement, there are data about
the anti-ischemic effect of quinapril on clinical variables of myo-
cardial ischemia in patients with coronary artery disease. Bussmann
et al. (3) have previously reported the results of a randomized,
double-blind, cross-over study of 16 men with coronary artery
disease receiving oral quinapril or placebo. They were able to show
that quinapril (10 mg) lead acutely, and after two weeks of
treatment, to a significant reduction in the extent of ST depression
during exercise electrocardiogram.
Taken together these data indicate that quinapril has an anti-
ischemic potential. However, we agree with Dr. Langobardi and
have this clearly stated in our paper, that we do not treat
myocardial blood flow values but patients with coronary artery
disease. Therefore, the unique, anti-ischemic potential of quinapril
in the treatment of patients with coronary artery disease must be
substantiated in large clinical trials. From our data quinapril seems
to be a promising choice for such studies.
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Pressure Relaxation of the
Left Ventricle and Filling Pressures
We read with great interest the article by Senzaki et al. (1). In a
careful study, the authors contrasted various methods for assessing
the time constant tau of left ventricular (LV) pressure decay. They
observed that pressure relaxation consistently deviated from a
monoexponential (ME) decay in dilated cardiomyopathy and
concluded that this deviation induced inaccuracies in the interpre-
tation of the time constant tau. They proposed that the use of the
hybrid-logistic (HL) method (2) resulted in more consistent data
fits in various heart diseases.
The manuscript by Senzaki et al. yields important novel infor-
mation on the analysis of LV pressure decay by focusing on the
goodness of fit. Pressure decay is the best reflection of myocardial
relaxation so far (3). Impaired myocardial relaxation will interfere
with LV filling and result in elevated end-diastolic pressure (4).
Senzaki et al. did not discuss the information that LV pressure
decay might provide on incomplete myocardial relaxation and, as a
consequence, on increased end-diastolic pressure. From a clinical
and physiological point of view, it appears to us that this issue is at
least as important as the goodness of fit.
We compared the ME method with the HL method. Single
beat aortic clamping was performed in healthy hearts from dogs
and rabbits (4). Leg elevation and phenylephrine administration
were performed in coronary surgery patients (5). The goodness of
fit was improved by the use of the HL-method in accordance to
the paper under scrutiny. In these experimental and clinical
studies, load dependence of LV pressure decay was less pro-
nounced with the HL-method, but still was present and even
highly significant. Changes in end-diastolic LV pressure induced
by increasing cardiac load were closely correlated with relaxation
rate, assessed both by the ME and HL methods (4,5). Of note, the
ME method provided a better prediction of changes in end-
diastolic pressure than did the HL method. The predictive value of
the ME method was confirmed in more than 120 coronary surgery
patients subjected to leg elevation (6).
Senzaki et al. suggested that increased load dependence of
pressure decay in congestive heart failure, as was observed in dogs
by Ishizaka (7) and in patients by Eichhorn (8), would not have
been observed if these authors would have used the HL method.
However, it should be noted that Ishizaka (7) not only reported
increased load dependency of pressure decay (ME method) in
cardiomyopathic hearts but also an upward shift of the diastolic
pressure-volume loops. Eichhorn showed in a subsequent study (9)
that load dependency of relaxation could predict the chronic
response to a beta-adrenergic blocking agent and decreased in
parallel with decreases in LV filling pressures.
Independently from its mathematical limitations and drawbacks,
the ME time constant of LV pressure decay remains a good
predictor of load-dependent changes of diastolic LV pressures. For
this reason the previous reports on increased load dependence of
pressure decay in cardiac overload and in diseased hearts keep for
us their scientific and clinical value.
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